Scholarlink

<p>There has been marked improvement in the clinical outcome of triple-negative breast cancer (TNBC) with the use of immune checkpoint blockade (ICB) although serious immune-related adverse effects are not uncommon. However, other subtypes including luminal ER+ and HER2+ breast cancers are largely unresponsive to ICB. Approximately 35% of TNBCs also do not fully respond to ICB. Here we hypothesize that improving priming by cross-presenting conventional dendritic cells (cDCs) with an agonistic CD40 antibody (aCD40) may be complementary to ICB. Systemic administration of aCD40 induced T cell proliferation and activation in tumor-draining lymph nodes and attracted effector T cells to the tumor bed from the periphery. This effect was largely due to activation and maturation of type 1 conventional dendritic cells (cDC1s). aCD40 alone slowed tumor growth and its combination with ICB cured tumor-bearing mice, accomplishing a “vaccine effect” and the immune-mediated rejection of tumor rechallenge. The anti-tumor effect of aCD40 was cDC1 and CD8 + T cell-dependent, whereas the rejection of secondary tumor rechallenge in cured mice required CD4 + T cells. Importantly, intra-tumoral administration of aCD40 combined with systemic or intra-tumoral ICB—to mimic neoadjuvant therapeutic approaches—induced complete regressions of both treated and distant tumors. These findings demonstrate aCD40 efficacy in preclinical models of breast cancer and further supports intra-tumoral administration of both aCD40 and ICB as an effective treatment that might limit systemic exposure and lower risk of immune-related toxicity.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Agonistic CD40 elicits CD8+ T-cell-dependent primary responses and CD4+ T-cell-dependent long-term immunity in breast cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月13日

查看全文
  • Casey Lam,
  • Olivia Lanchoney,
  • Vishnu Maddipatla,
  • Nune Markosyan,
  • Nikhil Joshi,
  • Xiaowen Hu,
  • Courtney Ray Fofana,
  • Shan Zeng,
  • Ronald P. DeMatteo,
  • Robert H. Vonderheide,
  • Jennifer Q. Zhang

摘要

There has been marked improvement in the clinical outcome of triple-negative breast cancer (TNBC) with the use of immune checkpoint blockade (ICB) although serious immune-related adverse effects are not uncommon. However, other subtypes including luminal ER+ and HER2+ breast cancers are largely unresponsive to ICB. Approximately 35% of TNBCs also do not fully respond to ICB. Here we hypothesize that improving priming by cross-presenting conventional dendritic cells (cDCs) with an agonistic CD40 antibody (aCD40) may be complementary to ICB. Systemic administration of aCD40 induced T cell proliferation and activation in tumor-draining lymph nodes and attracted effector T cells to the tumor bed from the periphery. This effect was largely due to activation and maturation of type 1 conventional dendritic cells (cDC1s). aCD40 alone slowed tumor growth and its combination with ICB cured tumor-bearing mice, accomplishing a “vaccine effect” and the immune-mediated rejection of tumor rechallenge. The anti-tumor effect of aCD40 was cDC1 and CD8 + T cell-dependent, whereas the rejection of secondary tumor rechallenge in cured mice required CD4 + T cells. Importantly, intra-tumoral administration of aCD40 combined with systemic or intra-tumoral ICB—to mimic neoadjuvant therapeutic approaches—induced complete regressions of both treated and distant tumors. These findings demonstrate aCD40 efficacy in preclinical models of breast cancer and further supports intra-tumoral administration of both aCD40 and ICB as an effective treatment that might limit systemic exposure and lower risk of immune-related toxicity.